MiR-199a-5p Decreases Esophageal Cancer Cell Proliferation Partially through Repression of Jun-B

Area of Science:

• Oncology
• Molecular Biology
• Gene Regulation

Background:

• MicroRNA (miR)-199a-5p exhibits tumor suppressor roles in various cancers, but its function in esophageal cancer remains unclear.
• Esophageal cancer is a significant global health concern, necessitating research into novel therapeutic targets and molecular mechanisms.
• The AP1 transcription factor, particularly its component Jun-B, is implicated in cancer progression and may be regulated by microRNAs.

Purpose of the Study:

• To investigate the role of miR-199a-5p in esophageal cancer.
• To elucidate the interaction between miR-199a-5p and Jun-B in esophageal cancer cells.
• To determine the functional consequences of this interaction on cancer cell proliferation and AP-1 activity.

Main Methods:

• Quantitative real-time PCR to assess miR-199a-5p and Jun-B expression levels in esophageal cancer tissues and cell lines.
• Western blotting to evaluate Jun-B protein expression.
• Biotinylated RNA-pull down assays and luciferase reporter assays to confirm direct interaction between miR-199a-5p and Jun-B mRNA.
• Cell proliferation assays and AP-1 promoter activity analysis following miR-199a-5p overexpression or Jun-B silencing.

Main Results:

• miR-199a-5p levels were significantly reduced in esophageal cancer specimens and cell lines, while Jun-B expression was elevated.
• Overexpression of miR-199a-5p led to decreased Jun-B mRNA stability, protein expression, and AP-1 promoter activity.
• A direct binding interaction between miR-199a-5p and Jun-B mRNA was experimentally validated.
• Both miR-199a-5p overexpression and Jun-B silencing significantly inhibited esophageal cancer cell proliferation.

Conclusions:

• miR-199a-5p functions as a tumor suppressor in esophageal cancer.
• The tumor-suppressive role of miR-199a-5p is mediated, in part, by the repression of Jun-B.
• Targeting the miR-199a-5p/Jun-B axis may offer a potential therapeutic strategy for esophageal cancer.